JP7006990B2 - 眼障害の処置のための組成物及び方法 - Google Patents

眼障害の処置のための組成物及び方法 Download PDF

Info

Publication number
JP7006990B2
JP7006990B2 JP2020526481A JP2020526481A JP7006990B2 JP 7006990 B2 JP7006990 B2 JP 7006990B2 JP 2020526481 A JP2020526481 A JP 2020526481A JP 2020526481 A JP2020526481 A JP 2020526481A JP 7006990 B2 JP7006990 B2 JP 7006990B2
Authority
JP
Japan
Prior art keywords
administration
formula
eye
pilocarpine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2020526481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503449A (ja
JP2021503449A5 (https=
Inventor
マヘッシュ カンドゥラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Publication of JP2021503449A publication Critical patent/JP2021503449A/ja
Publication of JP2021503449A5 publication Critical patent/JP2021503449A5/ja
Application granted granted Critical
Publication of JP7006990B2 publication Critical patent/JP7006990B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2020526481A 2017-11-17 2018-09-22 眼障害の処置のための組成物及び方法 Expired - Fee Related JP7006990B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201741041231 2017-11-17
IN201741041231 2017-11-17
PCT/IB2018/057342 WO2019097318A1 (en) 2017-11-17 2018-09-22 Compositions and methods for the treatment of eye disorders

Publications (3)

Publication Number Publication Date
JP2021503449A JP2021503449A (ja) 2021-02-12
JP2021503449A5 JP2021503449A5 (https=) 2021-05-13
JP7006990B2 true JP7006990B2 (ja) 2022-02-10

Family

ID=66540065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020526481A Expired - Fee Related JP7006990B2 (ja) 2017-11-17 2018-09-22 眼障害の処置のための組成物及び方法

Country Status (14)

Country Link
US (1) US10933052B2 (https=)
EP (1) EP3651747A4 (https=)
JP (1) JP7006990B2 (https=)
KR (1) KR102349776B1 (https=)
CN (1) CN111372576A (https=)
AU (1) AU2018367909B2 (https=)
BR (1) BR112020009361A2 (https=)
CA (1) CA3081553C (https=)
IL (1) IL274234B2 (https=)
MX (1) MX389626B (https=)
RU (1) RU2761436C1 (https=)
SG (1) SG11202004019SA (https=)
WO (1) WO2019097318A1 (https=)
ZA (1) ZA202002066B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386467B (es) * 2016-10-04 2025-03-18 Cellix Bio Private Ltd Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal)
MX392359B (es) * 2017-11-17 2025-03-24 Cellix Bio Private Ltd Compuestos, composiciones y metodos para el tratamiento de trastornos oculares y enfermedades cutaneas
AU2019214557A1 (en) * 2018-02-05 2020-08-20 Cellixbio Private Limited Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
EP4069220A4 (en) 2019-12-04 2024-04-24 Restore Vision, LLC. OPHTHALMIC FORMULATIONS FOR THE TREATMENT OF PRESBYOPIA
TWI819268B (zh) * 2020-01-16 2023-10-21 詹姆斯 Ｗ 希爾 藉由基因轉導改變眼睛顏色
MX2022014413A (es) * 2020-05-26 2022-12-07 Cellix Bio Private Ltd Formulaciones farmaceuticas de pilocarpina r-(+)-lipoato.
WO2023052974A1 (en) * 2021-09-29 2023-04-06 Avaca Pharma Private Limited Ocular compositions and methods for the treatment of ophthalmic diseases and disorders
US20250101009A1 (en) * 2022-11-19 2025-03-27 Iview Therapeutics, Inc. Compounds, Compositions and Methods for Treatment of Age-Related Ocular Disorders
WO2025230326A1 (ko) * 2024-04-30 2025-11-06 주식회사태준제약 필로카르핀을 포함하는 점안 조성물

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537522A (ja) 2001-06-07 2004-12-16 マリー−テレーズ ドロワ−ルフェ 眼表面異常の治療及び／又は予防薬の製造における抗酸化剤の使用
US20090156606A1 (en) 2007-12-15 2009-06-18 Anant Sharma Optical correction
JP2009541220A (ja) 2006-06-16 2009-11-26 インディジーン ファーマシューティカルズ インコーポレイテッド 糖尿病性高血糖および糖尿病合併症の制御のための抗糖尿病薬としてのメトホルミンｒ−（＋）リポエート
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US20140221467A1 (en) 2013-02-07 2014-08-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications
CN104387364A (zh) 2014-12-15 2015-03-04 南京工业大学 L-鸟氨酸硫辛酸复合盐及其制备方法和应用
WO2015103577A1 (en) 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
JP2016508140A (ja) 2012-12-28 2016-03-17 チョン クン ダン ファーマシューティカル コーポレーション カチオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物
JP2019531302A (ja) 2016-10-04 2019-10-31 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 口内乾燥症（ｘｅｒｏｓｔｏｍｉａ）の治療のための組成物および方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50250A (en) 1975-08-27 1980-01-31 Hydrophilics Int Inc Sustained release compositions comprising slats of pharmaceutically acitve bases with polymers containing acid groups
US4076942A (en) 1975-10-01 1978-02-28 Merck & Co., Inc. Crystalline dipilocarpinium pamoate
FR2424930A1 (fr) 1978-05-02 1979-11-30 Inst Khim Drevesiny Akadem Nouveaux polymeres d'alcoyl-1(oxo-5 alcoyl-4 tetrahydrofuryl-methyl(3)-5) imidazoles et d'ethers carboxyalcoyliques d'alcool polyvinylique, utiles notamment comme agents m-cholinomimetiques et leur procede de preparation
US4977176A (en) 1987-01-31 1990-12-11 Sandoz Ltd. Pilocarpine compounds which are used as pharmaceutical agents
NL8800099A (nl) 1987-01-31 1988-08-16 Sandoz Ag Pilocarpinederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
JP2771257B2 (ja) 1989-06-22 1998-07-02 岩城製薬株式会社 イミダゾール誘導体の製法
US5322942A (en) 1991-06-03 1994-06-21 Regents Of The University Of California Synthesis of optically active lactones from L-aspartic acid and intermediates thereof
DE4222459C2 (de) 1992-07-08 1995-09-14 Sigma Tau Ind Farmaceuti 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
DE4334135A1 (de) 1993-10-07 1995-04-13 Merck Patent Gmbh Verfahren zur Herstellung von Pilocarpin-Derivaten
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
US5811428A (en) 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
AU726522B2 (en) 1995-09-01 2000-11-09 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
CN1209809A (zh) 1996-01-22 1999-03-03 藤泽药品工业株式会社 新化合物
CN1152673C (zh) 1997-10-28 2004-06-09 坂东化学株式会社 皮肤贴附药片及其基片的制造方法
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
US6222039B1 (en) 1998-07-13 2001-04-24 Hoffman-La Roche Inc. Process for the preparation of chiral lactones
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
TWI283669B (en) 1999-06-10 2007-07-11 Allergan Inc Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
ES2307758T3 (es) 2001-06-05 2008-12-01 Lilly Icos Llc Derivados de pirazino (1',2':1,6)pirido(3,4-b)indol 1,4-diona.
WO2004014881A2 (en) 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
AU2003272608A1 (en) 2002-09-19 2004-04-08 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
DE10358539A1 (de) 2003-12-15 2005-07-07 Merck Patent Gmbh Carbonsäureamidderivate
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
PL2044056T3 (pl) 2006-07-14 2013-01-31 Novartis Ag Pochodne pirymidyny jako inhibitory ALK-5
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
US8673970B2 (en) 2008-02-21 2014-03-18 Sequoia Pharmaceuticals, Inc. HIV protease inhibitor and cytochrome p450 inhibitor combinations
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP2326625A1 (en) 2008-07-18 2011-06-01 Takeda Pharmaceutical Company Limited Benzazepine derivatives and their use as hstamine h3 antagonists
US20110091459A1 (en) 2008-12-11 2011-04-21 Auspex Pharmaceuticals, Inc. Imidazole modulators of muscarinic acetylcholine receptor m3
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2011113060A2 (en) 2010-03-12 2011-09-15 Trana Discovery, Inc. Antiviral compounds and methods of use thereof
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
KR20190039347A (ko) 2010-06-03 2019-04-10 알닐람 파마슈티칼스 인코포레이티드 활성제의 전달을 위한 생분해성 지질
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
RU2013129818A (ru) 2010-11-30 2015-01-10 Дженентек, Инк. Способы анализа и биомаркеры для гена lrrk2
WO2012079032A2 (en) 2010-12-09 2012-06-14 Trana Discovery, Inc. Compositions and methods of treating drug-resistant retroviral infections
US9388140B2 (en) 2011-03-31 2016-07-12 Bayer Intellectual Property Gmbh Substituted benzimidazoles
WO2012136531A1 (en) 2011-04-06 2012-10-11 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
JP2012230356A (ja) 2011-04-15 2012-11-22 Sumitomo Chemical Co Ltd 化合物、レジスト組成物及びレジストパターンの製造方法
GB201114448D0 (en) 2011-08-22 2011-10-05 Takeda Pharmaceutical Compounds and their use
US20140228384A1 (en) 2011-11-29 2014-08-14 Genentech, Inc. Assays and biomarkers for lrrk2
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
JP2015505542A (ja) 2012-01-28 2015-02-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ アザ複素環式化合物
WO2013144191A1 (de) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
JP6449880B2 (ja) 2013-08-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ピラジンアミド化合物
WO2015082376A2 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
WO2015082378A1 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
MA40060A (fr) 2014-07-01 2016-01-07 Takeda Pharmaceuticals Co Composés hétérocycliques et leur utilisation en tant qu'inhibiteurs gamma-t du récepteur orphelin apparenté aux récepteurs des rétinoïdes (ror) )

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004537522A (ja) 2001-06-07 2004-12-16 マリー−テレーズ ドロワ−ルフェ 眼表面異常の治療及び／又は予防薬の製造における抗酸化剤の使用
JP2009541220A (ja) 2006-06-16 2009-11-26 インディジーン ファーマシューティカルズ インコーポレイテッド 糖尿病性高血糖および糖尿病合併症の制御のための抗糖尿病薬としてのメトホルミンｒ−（＋）リポエート
US20090156606A1 (en) 2007-12-15 2009-06-18 Anant Sharma Optical correction
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
JP2016508140A (ja) 2012-12-28 2016-03-17 チョン クン ダン ファーマシューティカル コーポレーション カチオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物
US20140221467A1 (en) 2013-02-07 2014-08-07 Banavara L. Mylari Metformin derivatives for treating diabetes and diabetes complications
WO2015103577A1 (en) 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
CN104387364A (zh) 2014-12-15 2015-03-04 南京工业大学 L-鸟氨酸硫辛酸复合盐及其制备方法和应用
JP2019531302A (ja) 2016-10-04 2019-10-31 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 口内乾燥症（ｘｅｒｏｓｔｏｍｉａ）の治療のための組成物および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FREITAS, R. M.，The evaluation of effects of lipoic acid on the lipid peroxidation, nitrite formation and antioxidant enzymes in the hippocampus of rats after pilocarpine-induced seizures，Neuroscience Letters，2009年，Vol.455，pp.140-144，DOI:10.1016/j.neulet.2009.03.065
MENDES DE FREITAS, Rivelilson，Lipoic Acid Increases Hippocampal Choline Acetyltransferase and Acetylcholinesterase Activities and Improvement Memory in Epileptic Rats，Neurochem Res，2010年，Vol.35，pp.162-170，DOI：10.1007/s11064-009-0041-6

Also Published As

Publication number Publication date
CN111372576A (zh) 2020-07-03
IL274234B2 (en) 2023-02-01
RU2761436C1 (ru) 2021-12-08
CA3081553A1 (en) 2019-05-23
WO2019097318A1 (en) 2019-05-23
SG11202004019SA (en) 2020-05-28
MX389626B (es) 2025-03-20
CA3081553C (en) 2022-11-15
AU2018367909B2 (en) 2022-03-10
KR20200089292A (ko) 2020-07-24
IL274234A (en) 2020-06-30
AU2018367909A1 (en) 2020-05-07
US20200179343A1 (en) 2020-06-11
BR112020009361A2 (pt) 2020-10-13
JP2021503449A (ja) 2021-02-12
NZ763688A (en) 2021-10-29
MX2020004666A (es) 2022-01-26
EP3651747A4 (en) 2020-07-22
US10933052B2 (en) 2021-03-02
IL274234B (en) 2022-10-01
EP3651747A1 (en) 2020-05-20
KR102349776B1 (ko) 2022-01-10
ZA202002066B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
JP7006990B2 (ja) 眼障害の処置のための組成物及び方法
JP2021152048A (ja) 慢性疼痛の処置のための組成物及び方法
CN103338758B (zh) 叶酸‑雷米普利组合：具细胞保护性、神经保护性及视网膜保护性的眼科组合物
JP2021512876A (ja) 抗ムスカリン薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
JP7038437B2 (ja) 眼障害及び皮膚疾患の処置のための化合物、組成物、及び方法
CN105828813A (zh) 涉及治疗神经系统损伤的疾病的ω3脂肪酸组合物
JP2020100623A (ja) 炎症及び疼痛の治療のための組成物及び方法
JP2022516796A (ja) 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用
JP2022504410A (ja) パーキンソン病の処置のための組成物及び方法
CN115768433A (zh) 含有司培前列素的医药制剂
JP2021536439A (ja) 眼障害及び皮膚疾患の処置のための眼科用組成物及び方法
JP2022509174A (ja) 皮膚疾患及び眼疾患の処置のための眼科用組成物及び方法
JP6698669B2 (ja) 粘膜炎の治療のための組成物及び方法
JP2023547441A (ja) 萎縮型加齢黄斑変性、地図状萎縮および緑内障関連神経変性の処置において使用するためのｎｏ－ｐｄｅ５阻害剤
NZ763688B2 (en) Compositions and methods for the treatment of eye disorders
HK1190067B (en) Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210401

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210401

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211224

R150 Certificate of patent or registration of utility model

Ref document number: 7006990

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

LAPS Cancellation because of no payment of annual fees